読み込み中
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
前日終値
$0.5702
+$0.0102 · +1.82%
日中の時刻はETです。市場データは遅延する場合があります。
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
日中レンジ
現在 $0.5702
52週レンジ
現在 $0.5702
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
44
適正価値
センチメント
57
まちまち
リスク
90
極めて高いリスク
モメンタム
25
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
日中レンジ
現在 $0.5702
52週レンジ
現在 $0.5702
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 105.6万 USD | — | — | — | — |
| 粗利益 | −105.6万 USD | — | — | — | — |
| 研究開発 | 6051.8万 USD | 5582.1万 USD | 5178.5万 USD | 3462.7万 USD | 2542.1万 USD |
| 販売・一般管理 | 1894.4万 USD | 2041.8万 USD | 1707.6万 USD | 1656.9万 USD | 1141.2万 USD |
| 営業費用 | 7946.2万 USD | 7623.9万 USD | 6886.1万 USD | 5119.6万 USD | 3683.3万 USD |
| 受取利息 | 174.1万 USD | 505.8万 USD | 519.9万 USD | 70.1万 USD | — |
| 減価償却費と償却費 | 105.6万 USD | 137.3万 USD | 110.8万 USD | 97.5万 USD | 37.7万 USD |
| 営業利益 | −8051.8万 USD | −7623.9万 USD | −6886.1万 USD | −5119.6万 USD | −3683.3万 USD |
| 純利益 | −7580.1万 USD | −7126.9万 USD | −6446.5万 USD | −3768.5万 USD | −3063.7万 USD |
会社概要が更新されました 2026年10月11日.
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$2.50
上昇余地（338.44%）この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
